|
|
Article: Serono To Market Genentech's Raptiva In Europe, Other Areas.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
Genentech Inc. has the marketing bases covered - Xoma Ltd. on first, itself standing on second and now Serono SA manning third - for its psoriasis product, Raptiva. Now all it has to do is touch home plate by getting approval.
Genentech, of South San Francisco, signed an agreement giving Serono, of Geneva, exclusive rights to market Raptiva in areas outside the U.S., Japan and certain other Asian countries. Genentech and Xoma, of Berkeley, Calif., will handle U.S. sales, and Genentech retains rights to Japan and the certain Asian countries. But with Serono signed on, the world is now effectively wrapped in a Raptiva marketing blanket. ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|